MedTrace Logo

A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma

NCT07107178 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2025-08-06

No results posted yet for this study

Summary

The goal of this clinical trial is to learn about the safety, tolerability and preliminary effectiveness of a treatment for patients with advanced melanoma,regardless of gender, aged between 18 and 75 years (inclusive).

Participants will receive the investigational product intravenously every two or three weeks. The treatment will continue for a maximum of two years for those who do not show signs of disease progression or experience intolerable side effects.

Conditions

Interventions

DRUG

BT02

monoclonal antibody injection with intravenous administration every 2 or 3 weeks

Sponsors & Collaborators

  • Peking University Cancer Hospital and Institute

    collaborator OTHER

  • Biotroy Therapeutics

    lead INDUSTRY

Principal Investigators

  • Jun Guo, MD · Peking University Cancer Hospital & Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-08
Primary Completion
2027-05-31
Completion
2027-08-31
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07107178 on ClinicalTrials.gov